Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 67 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Taiho Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Taiho Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Taiho Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Taiho Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Taiho Pharmaceutical Co., Ltd.'s pipeline products

Reasons to buy

- Evaluate Taiho Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Taiho Pharmaceutical Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Taiho Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Taiho Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Taiho Pharmaceutical Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Taiho Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Taiho Pharmaceutical Co., Ltd. Snapshot 6
Taiho Pharmaceutical Co., Ltd. Overview 6
Key Information 6
Key Facts 6
Taiho Pharmaceutical Co., Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
Taiho Pharmaceutical Co., Ltd. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Taiho Pharmaceutical Co., Ltd. - Pipeline Products Glance 15
Taiho Pharmaceutical Co., Ltd. - Late Stage Pipeline Products 15
Phase III Products/Combination Treatment Modalities 15
Taiho Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Taiho Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Taiho Pharmaceutical Co., Ltd. - Unknown Stage Pipeline Products 20
Unknown Products/Combination Treatment Modalities 20
Taiho Pharmaceutical Co., Ltd. - Drug Profiles 21
(piperacillin sodium + tazobactam sodium) 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
(tegafur + gimeracil + oteracil) 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
(tipiracil + trifluridine) 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
orantinib 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
TAS-118 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
bilastine 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
TAS-106 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
paclitaxel 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
TAS-120 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ARH-1029 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
TAS-114 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
TAS-115 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
TAS-116 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
TAS-117 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
TAS-2104 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
TAS-2913 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
TAS-2985 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
TAS-5567 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecule to Inhibit S100B-p53 Interaction for Melanoma 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Taiho Pharmaceutical Co., Ltd. - Pipeline Analysis 46
Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Target 46
Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 48
Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 49
Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 50
Taiho Pharmaceutical Co., Ltd. - Recent Pipeline Updates 52
Taiho Pharmaceutical Co., Ltd. - Dormant Projects 62
Taiho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products 63
Discontinued Pipeline Product Profiles 63
suplatast tosilate 63
Taiho Pharmaceutical Co., Ltd. - Company Statement 64
Taiho Pharmaceutical Co., Ltd. - Locations And Subsidiaries 65
Head Office 65
Other Locations & Subsidiaries 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 67
Disclaimer 67

List of Tables
Taiho Pharmaceutical Co., Ltd., Key Information 6
Taiho Pharmaceutical Co., Ltd., Key Facts 6
Taiho Pharmaceutical Co., Ltd. - Pipeline by Indication, 2014 8
Taiho Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014 10
Taiho Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014 11
Taiho Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2014 12
Taiho Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2014 13
Taiho Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 14
Taiho Pharmaceutical Co., Ltd. - Phase III, 2014 15
Taiho Pharmaceutical Co., Ltd. - Phase II, 2014 16
Taiho Pharmaceutical Co., Ltd. - Phase I, 2014 17
Taiho Pharmaceutical Co., Ltd. - Preclinical, 2014 18
Taiho Pharmaceutical Co., Ltd. - Discovery, 2014 19
Taiho Pharmaceutical Co., Ltd. - Unknown, 2014 20
Taiho Pharmaceutical Co., Ltd. - Pipeline by Target, 2014 47
Taiho Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2014 48
Taiho Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2014 49
Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 51
Taiho Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2014 52
Taiho Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2014 62
Taiho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2014 63
Taiho Pharmaceutical Co., Ltd., Subsidiaries 65